Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress
- Results showed GNSC-001 met the primary safety endpoint and was well-tolerated in all study subjects, including 12-month follow-up.
- Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.
- Osteoarthritis affects more than 30 million Americans and is the leading cause of disability; GNSC-001 may have a role to play in helping these patients in a safe and efficacious manner.
Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA) demonstrated that it was safe and well tolerated.
These data will be delivered in a poster presentation at the European American Society of Gene & Cell Therapy’s (ESGCT) 30th Annual Congress which will be held October 24-27, 2023, in Brussels, Belgium. Genascence, a UF startup, licensed technology discovered by Dr. Steven Ghivizzani in UF’s College of Medicine Department of Orthopedics.
Read more about Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress.